Cargando…

Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study

AIMS: Atrial fibrillation (AF) risk factors translate into disease progression. Whether this affects women and men differently is unclear. We aimed to investigate sex differences in risk factors, outcome, and quality of life (QoL) in permanent AF patients. METHODS AND RESULTS: The Rate Control Effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kloosterman, Mariëlle, Crijns, Harry J G M, Mulder, Bart A, Groenveld, Hessel F, Van Veldhuisen, Dirk J, Rienstra, Michiel, Van Gelder, Isabelle C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657385/ https://www.ncbi.nlm.nih.gov/pubmed/31747018 http://dx.doi.org/10.1093/europace/euz300

Ejemplares similares

Assessment of sex-related differences and outcome in patients who underwent cryoballoon pulmonary vein isolation for atrial fibrillation: an observational cohort study
por: Ekrami, Neda Khalilian, et al.
Publicado: (2022)

Initial experience with pulsed field ablation for atrial fibrillation
por: Magni, Federico T., et al.
Publicado: (2022)

Young-onset atrial fibrillation: Sex differences in clinical profile, progression rate and cardiovascular outcome()
por: Marcos, Ernaldo G., et al.
Publicado: (2019)

Update on management of atrial fibrillation in heart failure: a focus on ablation
por: Mulder, Bart A, et al.
Publicado: (2022)

Identifying patients with atrial fibrillation recurrences after two pulmonary vein isolation procedures
por: Mulder, Bart A, et al.
Publicado: (2021)

Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study
por: Nguyen, Bao Oanh, et al.
Publicado: (2020)

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
por: van de Lande, Martijn E, et al.
Publicado: (2023)

Incidence and outcome of atrial fibrillation: diversity throughout Europe
por: Rienstra, Michiel, et al.
Publicado: (2021)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure
por: Brandes, Axel, et al.
Publicado: (2020)

Atrial fibrillation and heart failure temporality: does it matter?
por: Van Deutekom, Colinda, et al.
Publicado: (2022)

Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation
por: Van Noord, Trudeke, et al.
Publicado: (2005)

Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021)

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands
por: Crijns, H. J. G. M., et al.
Publicado: (2020)

Prevalence and Incidence of Atrial Fibrillation in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: (Additive) Value of Implantable Loop Recorders
por: Gorter, Thomas M., et al.
Publicado: (2023)

Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies
por: De With, Ruben R, et al.
Publicado: (2021)

Telomere length and incident atrial fibrillation – data of the PREVEND cohort
por: Siland, Joylene E., et al.
Publicado: (2017)

What should the C (‘congestive heart failure’) represent in the CHA(2)DS(2)‐VASc score?
por: Mulder, Bart A., et al.
Publicado: (2020)

Heart rate increase and inappropriate sinus tachycardia after cryoballoon pulmonary vein isolation for atrial fibrillation
por: van Deutekom, C., et al.
Publicado: (2021)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
por: Artola Arita, Vicente, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
por: Noordman, Alwin B. P., et al.
Publicado: (2021)

First-line treatment of persistent and long-standing persistent atrial fibrillation with single-stage hybrid ablation: a 2-year follow-up study
por: Magni, Federico T, et al.
Publicado: (2021)

Cluster Individuals Based on Phenotype and Determine the Risk for Atrial Fibrillation in the PREVEND and Framingham Heart Study Populations
por: Rienstra, Michiel, et al.
Publicado: (2016)

Reappraisal of Atrial fibrillation: interaction between hyperCoagulability, Electrical remodelling and Vascular destabilisation in the progression of AF (RACE V) Tissue Bank Project: study design
por: Gilbers, M. D., et al.
Publicado: (2021)

Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort
por: Van Deutekom, Colinda, et al.
Publicado: (2023)

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation
por: Nguyen, Bao-Oanh, et al.
Publicado: (2023)

Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V
por: De With, Ruben R, et al.
Publicado: (2020)

Relation of overweight and symptomatic atrial fibrillation: A case report
por: de Maat, Gijs E., et al.
Publicado: (2015)

Newly discovered atrial fibrillation: who(se) care(s)?
por: Crijns, Harry J G M, et al.
Publicado: (2020)

Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study
por: Van De Lande, M E, et al.
Publicado: (2023)

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial
por: Koldenhof, T, et al.
Publicado: (2023)

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V
por: Park Frausing, M H J, et al.
Publicado: (2023)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Lifestyle components: Self-reported physical activity, nutritional status, sleep quality and incident atrial fibrillation
por: Siland, Joylene E., et al.
Publicado: (2020)

Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation
por: Al-Jazairi, M. I. H., et al.
Publicado: (2019)

Rate control drugs differ in the prevention of progression of atrial fibrillation
por: Koldenhof, Tim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lnlp0ajgina858ujqjou3l8llc